Changeflow GovPing Healthcare & Life Sciences Patent Application for Cancer Treatment Compounds
Routine Notice Added Draft

Patent Application for Cancer Treatment Compounds

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085070A1) for heterocyclic CBL-B inhibitors intended for the treatment of cancer. The application was filed on April 7, 2025, by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application detailing novel compounds and compositions for cancer treatment, specifically targeting CBL-B inhibition. The application, filed by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN, outlines potential pharmaceutical uses and methods of making these compounds.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future patent protection for specific cancer treatments. Companies involved in oncology drug development should monitor this application and related patents to understand the intellectual property landscape and potential licensing or infringement considerations.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER

Application US20260085070A1 Kind: A1 Mar 26, 2026

Inventors

Yingzhi BI, Kenneth G. CARSON, Geraldine Cirillo HARRIMAN

Abstract

The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.

CPC Classifications

C07D 471/04 A61K 31/437 A61K 31/444 A61K 31/4545

Filing Date

2025-04-07

Application No.

19171907

View original document →

Named provisions

HETEROCYCLIC CBL-B INHIBITORS FOR THE TREATMENT OF CANCER

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085070A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Cancer Treatment
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!